June 10, 2023

Pavel Printsev - Director of Business Development at Bridge Biotherapeutics

Show Notes
Guest Profile

In this episode of the Life Science Success Podcast my guest is Pavel Printsev. Pavel is the Director of Business Development at Bridge Biotherapeutics. Prior to joining Bridge in early 2021 he was working at a South Korean VC firm. Pavel’s academic background is in Organic Chemistry and worked as a Research Scientist for several years. Since then, he has been active in advancing scientific development through global partnership, collaboration and investment between South Korea and the rest of the world.

Bridge Biotherapeutics is a small to mid-size Biotherapeutics company founded in 2015.
They have clinical-stage assets in nonsmall cell lung cancer, ulcerative colitis, and idiopathic pulmonary fibrosis.
They also acquired a next-generation biosensor detection company, which is a thousand times more sensitive than the current commercial ECL biosensor device.
Bridge Biotherapeutics is focused on maximizing resources and following the path where they see the most opportunity.
Pavel Printsev is inspired by people who have become masters in their respective fields and are dedicated, motivated, ambitious, and do not give up.
Concerns include the gap in research and unmet medical needs for indications that may not be profitable.
Pavel is excited about the advancements in AI and deep learning, gene editing, and precision medicine.

Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.

Pavel Printsev

Director

Pavel Printsev is the Director of Business Development at Bridge Biotherapeutics, a publicly-traded, South Korean, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including ulcerative colitis, fibrotic diseases, and cancers. The company also has an independently run research center in Boston, USA, that is developing its own in-house discovery programs, currently focusing on oncology.

Pavel has been living and working in South Korea for over ten years, where he has helped several domestic pharma, venture capital, and biotech companies expand and grow their businesses abroad. Pavel is also involved in company creation, as he serves as a panelist on Baselaunch’s (Basel-based biotech incubator and accelerator) selection and review committee.

Pavel graduated from the University of Toronto with a specialist degree in Chemistry and went on to receive his Master’s degree at Seoul National University in Organic Chemistry.